While the compound is still untested in humans, Zuo and Olson’s Molecular Psychiatry paper about it shows that sort of promise. UC Davis chemical neuroscientist David E. Olson. Johanna van de ...

A compound, hydroxynorketamine (HNK), has been identified by researchers that may treat symptoms of depression just as effectively and rapidly as ketamine, without the unwanted side effects ...

Fast-acting ketamine by-product – may be future therapy for Alzheimer’s, Parkinson’s There is new hope for people suffering from depression. Researchers have identified a compound, hydroxynorketamine ...

According to Fortune Business Insights, the fibromyalgia treatments market was valued at $764 million in 2020 and will be worth $1.4 billion in 2027 with a Compound Annual Growth Rate (CAGR) of 9. ...